Disulfiram for Cocaine-Alcohol Abuse - 3

This study has been completed.

First Received on September 20, 1999. Last Updated on August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	VA Connecticut Healthcare System
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000278

Purpose

The purpose of this study is to evaluate disulfiram for cocaine-alcohol abuse.

Condition	Intervention	Phase
Alcohol-Related Disorders Cocaine-Related Disorders	Drug: Disulfiram	Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Disulfiram for Cocaine-Alcohol Abuse

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Ethanol Disulfiram

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Side effects
Cocaine effects

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years to 50 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000278

Locations

United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

VA Connecticut Healthcare System

Investigators

Principal Investigator:

Thomas R Kosten, M.D.

VA Connecticut Healthcare System

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000278 History of Changes
Other Study ID Numbers:	NIDA-09250-3, P50-09250-3
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Alcoholism
Alcohol-Related Disorders
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Disulfiram

Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Alcohol Deterrents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 09, 2012